Results 1 to 10 of about 300,077 (226)

Polycythemia Vera Revealed by Acute Myocardial Infarction: A Case Report [PDF]

Reports
Background and Clinical Significance: Polycythemia vera is a myeloproliferative neoplasm associated with a high thrombotic risk. Although this association is well recognized, acute coronary syndrome as the initial manifestation of polycythemia vera is ...
Jéni Quintal, Raquel Flores, Tatiana Duarte, Ana Santo António, Filipe Seixo   +4 more
doaj   +2 more sources

Current management strategies for polycythemia vera and essential thrombocythemia

Blood Reviews, 2020
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiovascular events, a varying burden of symptoms, and an intrinsic risk of evolution to secondary forms of myelofibrosis and ...
Paola Guglielmelli, Alessandro M Vannucchi   +1 more
exaly   +2 more sources

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Blood, 2019
Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
Abdulraheem Yacoub, John Mascarenhas, Josef T Prchal   +2 more
exaly   +2 more sources

Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

PLoS ONE, 2020
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis are hematopoietic stem cell disorders and share driver mutations that either directly activate the thrombopoietin receptor, MPL, or activate it ...
Jerry L Spivak, Akil Merchant, Donna M Williams, Ophelia Rogers, Wanke Zhao, Amy Duffield, Linda S Resar, Alison R Moliterno, Zhizhuang J Zhao   +8 more
doaj   +2 more sources

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

Haematologica, 2020
We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2).
Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, Mads Emil Bjørn, Christen Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Dustin Andersen Patel, Lise Mette Rahbek Gjerdrum, Daniel El Fassi, Torben A. Kruse, Thomas Stauffer Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Christina Ellervik, Niels Pallisgaard, Mads Thomassen, Lasse Kjær, Vibe Skov, Hans Carl Hasselbalch   +19 more
doaj   +2 more sources

Givinostat: an emerging treatment for polycythemia vera

Expert Opinion on Investigational Drugs, 2020
Introduction Polycythemia vera (PV), a Philadelphia chromosome-negative myeloproliferative neoplasm, is characterized by panmyelosis, pancytosis, and a JAK2 mutation.
Helen T Chifotides, Prithviraj Bose, Srdan Verstovšek   +2 more
exaly   +2 more sources

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

Haematologica, 2019
Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children ...
Jean-Christophe Ianotto, Natalia Curto-Garcia, Marie Lauermanova, Deepti Radia, Jean-Jacques Kiladjian, Claire N. Harrison   +5 more
doaj   +2 more sources

Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculatory disturbances, and ...
A. Tefferi, T. Barbui
semanticscholar   +1 more source

Polycythemia vera is a medical condition characterized by raised hematocrit. Owing to increased viscosity, the blood flow in the vessels become sluggish leading to the clinical features of polycythemia such as headache, blurring of vision, red skin, dizzi

Journal of Bahria University Medical and Dental College, 2021
Polycythemia vera is a medical condition characterized by raised hematocrit. Owing to increased viscosity, the blood flow in the vessels become sluggish leading to the clinical features of polycythemia such as headache, blurring of vision, red skin ...
Nabeela Iqbal, Syed Khalid Shah, Shamima Haneef   +2 more
doaj   +1 more source

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Journal of Clinical Oncology, 2023
PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms.
C. Harrison, J. Nangalia, R. Boucher, Aimee E Jackson, C. Yap, J. O'Sullivan, Sonia Fox, Isaak Ailts, A. Dueck, H. Geyer, Ruben A. Mesa, W. Dunn, Eugene Nadezhdin, N. Curto-Garcia, A. Green, B. Wilkins, J. Coppell, J. Laurie, M. Garg, J. Ewing, S. Knapper, Josephine Crowe, Frederick Chen, I. Koutsavlis, A. Godfrey, S. Arami, M. Drummond, J. Byrne, F. Clark, Carolyn Mead-Harvey, E. J. Baxter, M. McMullin, A. Mead   +32 more
semanticscholar   +1 more source